Science News
from research organizations

Ozanimod as effective in treating ulcerative colitis, study shows

Date:
May 4, 2016
Source:
University of California - San Diego
Summary:
Ozanimod, a novel drug molecule, is moderately effective in the treatment of ulcerative colitis, researchers have demonstrated. Ulcerative colits is a debilitating autoimmune disease that causes chronic diarrhea.
Share:
FULL STORY

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

"This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation," said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health. "In addition to inducing remission in patients, the experimental drug reduced rectal bleeding and healed the mucosal lining of the intestine."

Ulcerative colits is a debilitating autoimmune disease that causes chronic diarrhea. One of the disease's defining characteristics is an abnormal accumulation of lymphocytes or T-cells in the lining of the gut. This activation of immune cells causes inflammation resulting in chronic, painful bowel movements. To counter this activity, ozanimod, a sphingosime 1-phospahte receptor modulator, halts the body's ability to recruit cells for an immune response.

"A one milligram pill of the drug induced clinical remission at week eight," said Sandborn. "Unlike other currently available drugs for inflammatory bowel disease, ozanimod can be orally administered and does not suppress the immune system to the point of increasing likelihood of infection or cancer."

Patients in the study were randomized to ozanimod 0.5 mg, 1.0 mg, or placebo. The most common side effects were anemia and headache.

Other symptoms of ulcerative colitis include intestinal bleeding and weight loss. Bowel obstruction, colon cancer, and malnutrition can also occur, resulting in hospitalization and the possible need for surgical removal of portions of the bowel and colon.

The Inflammatory Bowel Disease (IBD) Center at UC San Diego Health is dedicated to diagnosing and treating people with IBD from around the world. The center's leadership in IBD medical research means patient access to clinical trials for the newest therapies and advanced surgical techniques for the treatment of this challenging condition. Care is provided by a multidisciplinary team of specialists in gastroenterology, endoscopy, oncology, surgery, transplantation and radiology.


Story Source:

Materials provided by University of California - San Diego. Original written by Jackie Carr. Note: Content may be edited for style and length.


Journal Reference:

  1. William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Severine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine, 2016; 374 (18): 1754 DOI: 10.1056/NEJMoa1513248

Cite This Page:

University of California - San Diego. "Ozanimod as effective in treating ulcerative colitis, study shows." ScienceDaily. ScienceDaily, 4 May 2016. <www.sciencedaily.com/releases/2016/05/160504174848.htm>.
University of California - San Diego. (2016, May 4). Ozanimod as effective in treating ulcerative colitis, study shows. ScienceDaily. Retrieved May 25, 2017 from www.sciencedaily.com/releases/2016/05/160504174848.htm
University of California - San Diego. "Ozanimod as effective in treating ulcerative colitis, study shows." ScienceDaily. www.sciencedaily.com/releases/2016/05/160504174848.htm (accessed May 25, 2017).

RELATED STORIES